| 项目编号 |
PRJCA025657 |
| 项目标题 |
A multicenter Phase Ib/II clinical study of pyrrotinib and Darcilil (SHR6390) combined endocrine therapy in double-receptor-positive (ER+/HER2+) advanced breast cancer |
| 涉及领域 |
Medical |
| 数据类型 |
Genetic, metabolic and other data
|
| 物种名称 |
Homo sapiens
|
| 描述信息 |
A multicenter Phase Ib/II clinical study of pyrrotinib and Darcilil (SHR6390) combined endocrine therapy in double-receptor-positive (ER+/HER2+) advanced breast cancer(PLEASURABLE(LORDSHIPS 3.0 YBCSG-20-01)) |
| 样品范围 |
Multiisolate |
| 发布日期 |
2024-04-26 |
| 项目资金来源 |
| 机构 |
项目类型 |
授权项目ID |
授权项目名称 |
| NA
|
|
NA
|
|
|
|
| 提交者 |
weiqing ge
weiqing
ge (weiqing.ge@hengrui.com)
|
| 提交单位 |
Jiangsu Hengrui pharmaceutical Co.LTD |
| 提交日期 |
2024-04-26 |
